Small Pharma’s Intellectual Property Portfolio Flourishes with Exciting Breakthroughs

May 26, 2023

Eight notices of allowance and five new patents granted in key international jurisdictions LONDON, May 25, 2023 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: (OTCQB: DMT) A biotechnology company that focuses on short-term psychedelic-assisted therapies for mental health conditions, DMTTF) (the “Company” or “Small Pharma”) today announces an update to its intellectual property (“IP”) portfolio, demonstrating significant progress the Company has already made in 2023.

A multi-layered intellectual property (IP) strategy with four primary areas of protection is Small Pharma’s goal for safeguarding its pipeline programs. The following are protected areas: Piece of Issue, covering novel medication substances; Therapeutic Compositions and Their Medical Uses, including Product of a drug, including drug formulations; also, Manufactured Course, covering the novel and effective combination of high immaculateness drug substance at scale.

The company has acquired five new granted patents since the previous IP portfolio update on February 1, 2023, with three more anticipated to be granted by May 31, 2023. In addition, it has received five Notices of Allowance for patents. The extra IP covers the four centered areas of assurance and various business sectors, fortifying the Organization’s worldwide IP position.

The following is a summary of the new patent grants and Notices of Allowance.

DescriptionMarketPatent No.Status
Composition of

For certain deuterated homologues of certain tryptamine compoundsUSA11,578,039Granted
For certain deuterated homologues of certain tryptamine compoundsNew
For certain deuterated analogues of N,N, dimethyltryptamine (“DMT”)GB2 592 822Grant expected
after May 22, 2023
For a group of deuterated homologues of DMTUSA11,660,289Grant expected on
May 30, 2023
For a group of deuterated homologues of DMTEurope4 031 529Notice of
Medical Use

Of certain deuterated analogues of DMTGB2 586 940Grant expected
after May 25, 2023
Medical use and therapeutic compositions of a group of deuterated homologues of DMTAustralia2021204158Notice of
Medical use and therapeutic compositions of a group of deuterated homologues of DMTNew Zealand794833Notice of
Therapeutic compositions of a group of deuterated homologues of DMTJapan2022-574099Notice of
Drug Product
Novel optimized injectable formulation of DMT based compoundsAustralia2021334933Granted
Therapeutic solid dosage forms of deuterated DMT analoguesGB2 595 776Granted
Synthetic Route 
Novel efficient synthesis of high purity DMT and deuterated DMT analogues at scaleUSA11,643,390Granted
Novel efficient synthesis of high purity DMT and deuterated DMT analogues at scaleCanada3160337Notice of

As of May 24, 2023, Little Pharma’s IP portfolio comprises of 19 conceded licenses, with 97 permitted or forthcoming. The protection that applies to each pipeline program of the company is outlined below.

Candidate / ProjectRelevant Patents in Portfolio 
(No. active patents / pending patent applications)
SPL0261,  SPL0282, SPL02934 granted patents and 31 allowed and pending applications
SPL0286 granted patents, 37 allowed and pending applications
SPL028, SPL0298 allowed and pending applications
SPL029 4 granted patents, 11 allowed and pending applications
Non-psychedelic / othergranted patents, 10 allowed and pending applications

1Intravenous or intramuscular DMT
2 Injectable deuterated DMT series
3 Oral tryptamine series

George Tziras, CEO of Little Pharma said: ” Our group has gained extraordinary headway this year to additionally reinforce our exclusive IP position in key worldwide business sectors. Each of our pipeline programs continues to be protected by multiple layers of intellectual property, enhancing their commercial potential. We are pleased that multiple jurisdictions continue to recognize our efforts to invest in the creation of novel treatment innovations for patients.

About Small Pharma: Small Pharma is a biotechnology company working on a pipeline of short-term psychedelic-assisted treatments for mental health issues. At the moment, the company’s primary focus is on investigating novel depression treatment options. Little Pharma’s lead competitor, SPL026, is a restrictive manufactured detailing of N, N-dimethyltryptamine. The U.K. Medicines and Healthcare Products Regulatory Agency (the “MHRA”) awarded the company with an Innovation Passport designation for IV SPL026 with supportive therapy for Major Depressive Disorder. The company is working to advance the clinical programs of SPL026 and SPL028 for the treatment of mental health conditions. Likewise, Little Pharma has a pipeline of exclusive preclinical resources being developed.

Source –

Leave a Comment